What type of study is this?

September 10, 2025ERJ Open ResearchOpen Access

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab (an anti-IL-33 mAb) in early onset asthma

View Full Paper

Ask AI

Bookmark

Authors

Randomised trial assessed tozorakimab effects on FEV1 in adults with asthma, suggesting potential in patients with exacerbations.

Tozorakimab did not significantly improve pre-BD FEV1 compared to placebo in the overall population at week 16.
In patients with ≥2 prior exacerbations, tozorakimab showed a notable FEV1 improvement, indicating potential efficacy.
Observational analysis assessed FEV1 changes and safety in a randomised phase 2a framework over a 16-week period.
Although primary endpoints were not met, signals of efficacy in specific subgroups highlight the need for further research.

Corren et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark